Alps Advisors Inc Bio Atla, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$2.3 - $8.25 $621 - $2,227	-270 Reduced 0.86%	31,115 $83,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $197,411 - $345,548	31,385 New	31,385 $258,000
Q2 2022 Aug 11, 2022	SELL	$2.13 - $5.38 $81,351 - $205,478	-38,193 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $19,438 - $83,345	-4,438 Reduced 10.41%	38,193 $191,000
Q4 2021 Feb 09, 2022	BUY	$19.0 - $30.95 $22,743 - $37,047	1,197 Added 2.89%	42,631 $837,000
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $27,673 - $41,115	-940 Reduced 2.22%	41,434 $1.22 Million
Q2 2021 Aug 11, 2021	BUY	$38.07 - $56.17 $1.61 Million - $2.38 Million	42,374 New	42,374 $1.8 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.